Navigation Links
FDA Approves New Dosage Strength for INTELENCE®
Date:1/3/2011

sitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema)

  • Monitor clinical status including liver transaminases, and initiate appropriate therapy  
  • Delay in stopping INTELENCE treatment after the onset of severe rash may result in a life-threatening reaction
  • Fat Redistribution: Redistribution and/or accumulation of body fat have been observed in patients receiving antiretroviral (ARV) therapy. The causal relationship, mechanism, and long-term consequences of these events have not been established
  • Immune Reconstitution Syndrome: has been reported in patients treated with ARV therapy, including INTELENCE

  • Use in Specific Populations

  • Hepatic Impairment: INTELENCE should be used with caution in patients with severe hepatic impairment (Child-Pugh Class C) as pharmacokinetics of INTELENCE have not been evaluated in these patients
  • Pregnancy Category B:  INTELENCE should be used during pregnancy only if the potential benefit justifies the potential risk. No adequate and well-controlled studies have been conducted in pregnant women

  • Adverse Reactions

  • The most common adverse drug reactions (> or = 2%) of at least moderate intensity (> or = Grade 2) reported in patients taking INTELENCE and that occurred at a higher rate compared with placebo were rash (10% vs 3%) and peripheral neuropathy (4% vs 2%)

  • Drug Interactions

  • INTELENCE should not be coadministered with the following ARVs: tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, full-dose ritonavir (600 mg bid), protease inhibitors administered without low-dose ritonavir, and other NNRTIs
  • INTELENCE should not be co-administered with carbamazepine, phenobarb
    '/>"/>

  • SOURCE Tibotec Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
    3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
    4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
    5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
    6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
    7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
    8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
    9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
    10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
    11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... , Sept. 2, 2015  Seeger Weiss LLP ... bellwether trial will commence October 13, 2015. ... the 510K fast-track approval program, Zimmer NexGen knee implant ... only requires that companies provide evidence that the product ... in order to gain permissions. In ...
    (Date:9/2/2015)... SAN DIEGO , Sept. 2, 2015  Neurocrine ... Tim Coughlin , Chief Financial Officer of Neurocrine ... Conference in New York City . ... September 9 at 11:25am ET (8:25am PT).  The presentation ... Company,s website at http://www.neurocrine.com .   ...
    (Date:9/2/2015)... QC , Sept. 2, 2015 Demers Ambulances ... (EEP) Inc. as their new dealer for the states of ... and Tennessee . "This ... customers," said Benoit Lafortune , Executive Vice-President for Demers ... Mississippi and Alabama ...
    Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2
    ... Animal Health has launched its second product in the ... milbemycin oxime), a broad-spectrum parasiticide that kills fleas and ... infestations, the prevention of heartworm disease and the treatment ... in dogs and puppies 8 weeks and older, and ...
    ... 17, 2011 SFA Marketing today announced a ... exclusively to working with medical device manufacturers. SFA ... more than 20 years experience working with clients ... (Logo: http://photos.prnewswire.com/prnh/20110117/NY30375LOGO) "In response ...
    Cached Medicine Technology:Elanco Launches Broad-Spectrum Canine Parasiticide 2Elanco Launches Broad-Spectrum Canine Parasiticide 3Elanco Launches Broad-Spectrum Canine Parasiticide 4
    (Date:9/2/2015)... ... 02, 2015 , ... The 2015 China Overseas Investment and ... business conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai ... will feature leading EB-5 industry professionals and Chinese private equity partners looking for ...
    (Date:9/2/2015)... ... September 02, 2015 , ... World Patent Marketing, a vertically ... safety invention that protects people from crime and other hostile situations. , "The ... CEO and Creative Director of World Patent Marketing. "The industry is growing at ...
    (Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
    (Date:9/2/2015)... ... September 02, 2015 , ... ... helping to bring awareness to International Overdose Awareness Day. The goal is to ... recognize the warning signs so that they may get help. , ...
    (Date:9/2/2015)... ... 02, 2015 , ... The payroll conference theme this year ... education covering legislative updates, including unemployment, global payroll best practices, and the latest ... Ultimate Software, the American Payroll Association, Barnett Associates, and the IRS, will keep ...
    Breaking Medicine News(10 mins):Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2
    ... The Generic Pharmaceutical Association (GPhA) will discuss the results ... healthcare market intelligence company, revealing that generic pharmaceutical utilization has ... system in the last decade., What: ... ...
    ... Suction Provides Permanent Reduction of Excessive Sweat and Smells , ... ... sweating and body odor affects 176 million people and in most ... breakthrough procedure, Hypo Lipo , ( Axillary Curettage Suction ) ...
    ... 7 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... quarter ended March 31, 2009. "Our focus for the ... the NDA submission for pixantrone while we implemented final ... needed operating capital on the least dilutive terms possible ...
    ... 20% to $0.49 per outstanding common share from ... in Q1 2008)- Improved average monthly revenue per ... occupancy was 88.7%, down from 90.0% in Q1 ... to $497.9 million- Improved Facility Operating Income by ...
    ... - Sanofi Pasteur committed to increasing its seasonal ... production capacity in the U.S. -SWIFTWATER, Pa. and ... vaccines division of sanofi-aventis Group (EURONEXT: SAN and ... the U.S. Food and Drug Administration (FDA) has ...
    ... 125,000-member Indiana American Legion today challenged the Indiana General ... plainly on behalf of the youngsters at the Indiana ... on legislators to "not use the current budget impasse ... announced by the Indiana State Department of Health, would ...
    Cached Medicine News:Health News:Dr. Elliot Jacobs' New 'Hypo Lipo' Procedure Permanently Reduces Hyperhidrosis and Body Odor 2Health News:Dr. Elliot Jacobs' New 'Hypo Lipo' Procedure Permanently Reduces Hyperhidrosis and Body Odor 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 2Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 4Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 5Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 6Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 2Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 3Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 4Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 5Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 6Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 7Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 8Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 9Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 10Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 11Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 12Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 13Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 14Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 15Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 16Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 17Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 18Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 19Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 20Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 21Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 22Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 5Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 6Health News:Legion Demands 'Courage' From Legislators in Battle Over Children's Home 2
    ... Olympus TrueView II telescopes are based on ... unique wide field of view allows a tremendous ... view supports easy navigation in the joint with ... new quick lock mechanism for tight and secure ...
    ... WASCA Analyzer provides youwith new, exciting possibilities ... the WASCA Analyzeranalyzes the optical properties of ... the retina. In addition to refractive values, ... aberrations which were largely ignored in the ...
    ... Flow Unit is a flexible, total solution. , ... operating theaters since 1983. A major part of ... extensive experience from all the different areas of ... , ,Kojair Tech Oy is a comprehensive supplier. ...
    The Universal Knee Positioner(s)™ reduces surgeon fatigue while assisting in the stabilization of a patient's leg during surgury....
    Medicine Products: